Form 4 for AMRX Amneal Pharmaceuticals, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001628280-25-000581 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-06 | 2025-01-02 | AMRX | Patel Gautam | Dir | S - Sale | $8.01 | -17.4K | 2.03M | -0.8% | -$139.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-01-02 | S | D | 17,410 | $8.01 | 2,031,476 | D | — | — | (F1) These transactions occurred automatically pursuant to a plan adopted by the Reports Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |